Mirati Therapeutics

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Mirati Therapeutics reports successful KRAZATI launch amidst financial challenges

Mirati Therapeutics had a transformative year with the successful launch of KRAZATI for KRAS G12C mutated lung cancer.
Despite a net loss in Q4 2022, the company ended the year with a strong cash position and positive market feedback.
Challenges include financial losses, maximizing target inhibition with PRMT5 inhibitors, and regulatory hurdles for Phase 3 trials.
Opportunities lie in collaborations, combination therapies, Phase 3 trials, and advancing pipeline products for future growth.

Mirati Therapeutics reports strong Q1 performance and advances pipeline

Mirati Therapeutics showcased a strong financial performance in Q1 2023, driven by the successful launch of KRAZATI and progress in clinical studies for MRTX1133. The company's commitment to advancing its pipeline and addressing inquiries from analysts reflects a strategic focus on innovation and stakeholder engagement. Despite facing challenges such as a significant net loss, Mirati remains well-positioned with a robust cash position and promising growth opportunities.

Mirati Therapeutics reports strong Q2 performance and navigates strategic challenges

Mirati Therapeutics showcased strong commercial performance, promising clinical data, and proactive financial management strategies in its Q2 2023 Earnings Call.
While facing challenges in market positioning, trial complexities, and operational management, the company remains well-positioned to capitalize on opportunities in advancing its pipeline and optimizing financial performance.
Analysts' inquiries highlighted key areas of interest and concern, signaling the importance of strategic decision-making, regulatory navigation, and competitive positioning for Mirati's future success.
Overall, Mirati's focus on innovation, patient outcomes, and financial sustainability underscores its commitment to driving therapeutic advancements, addressing unmet medical needs, and delivering long-term value to stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirati Therapeutics Inc is a Biotechnology company located in 9363 Towne Centre Dr, San Diego, CA, United States.

Mirati (MRTX) submits an investigational new drug application to the FDA for MRTX1719 for the treatment of methylthioadenosine phosphoylase-deleted cancers.

Mirati (MRTX) to Begin Clinical Study in MTAP-Deleted Cancers

SAN DIEGO, Nov. 17, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to evaluate the Company's synthetic lethal PRMT5 inhibitor, MRTX1719, for the treatment of methylthioadenosine phosphoylase (MTAP)-deleted cancers. MRTX1719 has demonstrated in preclinical studies to be a potent, selective inhibitor of the PRMT5 / methylthioadenosine (MTA) complex.

Mirati Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration of MRTX1719 to Treat MTAP-Deleted Cancers

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) a clinical-stage oncology company, today announced that it intends to offer and sell in an underwritten public offering $500 million of shares of its common stock. In addition, Mirati expects to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the total shares offered in the public offering at the public offering price, less the underwriting discounts and commissions.

Mirati Therapeutics Announces Proposed Public Offering of Common Stock

Mirati's (MRTX) third-quarter earnings beat estimates. It initiates the NDA submission for adagrasib in second-line NSCLC.

Mirati (MRTX) Beats on Q3 Earnings, Begins NDA Adagrasib Filing

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will take part in a fireside chat at the Stifel Healthcare Conference 2021, which will be webcast on November 16 at 8:20 a.m. P.T. / 11:20 a.m.

Mirati Therapeutics to Participate in the Stifel 2021 Virtual Healthcare Conference

In its Q3 earnings release, Mirati Therapeutics Inc (NASDAQ: MRTX) posted preliminary results from the Phase 1b cohort of the KRYSTAL-1 study evaluating adagrasib plus Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in KRAS-mutated first-line non-small cell lung cancer (NSCLC). The Company said that a combination of adagrasib and Keytruda posted four partial responses among eight previously untreated patients.

Mirati Posts More Responses For Adagrasib-Keytruda Combo In Lung Cancer Setting

Mirati Therapeutics, Inc. (MRTX) CEO David Meek on Q3 2021 Results - Earnings Call Transcript

SAN DIEGO, Nov. 8, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2021 and recent corporate updates. "Mirati is aggressively focused on executing its strategy to deliver targeted cancer medicines to patients, and is well positioned for sustained growth from our differentiated research and development capabilities," said David Meek , chief executive officer, Mirati Therapeutics, Inc. "Our recent positive clinical updates for adagrasib reinforce a best-in-class profile, including topline results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study in patients with KRASG12C-mutated lung cancer, where we expect to launch in the U.S. next year, as well as encouraging results in KRASG12C-mutated colorectal and pancreatic cancers, which were presented at recent medical congresses.

Mirati Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate Updates

Mirati is competing with Amgen in the KRAS G12C mutant NSCLC space.

Mirati: Running On Good Science And A Lot Of Enthusiasm

SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Mirati Therapeutics, Inc. (NASDAQ: MRTX) for violations of federal securities laws. On November 1, 2021, Mirati, in an SEC filing, disclosed that certain executives would no longer be serving in their positions.

(MRTX) Alert: Did You Lose Money on Your Mirati Therapeutics Investment? Contact Johnson Fistel Regarding Investigation

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will announce financial results for the third quarter of 2021 and recent corporate updates on Monday, November 8. During a conference call at 4:30 p.m.

Mirati Therapeutics to Report Financial Results for Third Quarter 2021 and Recent Corporate Updates on November 8, 2021

Shares of Mirati Therapeutics, Inc. (NASDAQ: MRTX) are retreating sharply Monday following two executive departures. What Happened: Mirati, a clinical-stage targeted oncology company, said its Chief Operating Officer Daniel Faga and Chief Medical Officer Joseph Leveque have stepped down from their respective roles.

Mirati Therapeutics COO, CMO Exit, Completing Management Overhaul

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Mirati (MRTX) Q3 Earnings Expected to Decline

SAN DIEGO, Oct. 7, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced a non-exclusive clinical collaboration agreement with Sanofi to evaluate the combination of adagrasib, the Company's investigational KRASG12C inhibitor, with Sanofi's investigational SHP2 inhibitor SAR442720, also known as RMC-4630. The Phase 1/2 dose escalation and expansion study will evaluate the combination in patients with previously-treated non-small cell lung cancer (NSCLC) and KRASG12C mutations.

Mirati Therapeutics to Collaborate with Sanofi on Phase 1/2 Study Evaluating Combination of adagrasib with a SHP2 Inhibitor in KRAS G12C-mutated Lung Cancer

Biogen

Merck

Even after recently agreeing to shell out $11.5 billion to acquire Acceleron Pharma Inc. ( XLRN , Financial), Merck & Co. Inc. ( MRK , Financial) says it's not done in its quest for deals aimed at diversifying its business. The more than $200 billion pharmaceutical giant wants to expand its offerings to soften the blow when its mega-blockbuster drug, Keytruda, loses patent protection around 2028, according to FiercePharma.

Biogen, Mirati and Arcturus Reportedly on Merck's Radar

Merck & Co Inc (NYSE: MRK) remains in a deal-hunting mode despite its recent $11.5 billion acquisition of Acceleron.  Related:   Merck Seals Acceleron Pharma Deal For $180/Share: Highlights.

Merck Keeps M&A Mode On With Mirati, Biogen, mRNA Companies On Radar: FT

SAN DIEGO, Oct. 4, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place October 7 - 10, 2021. The Company will present preclinical data evaluating MRTX1719, the selected clinical candidate from our MTA-cooperative PRMT5 inhibitor program, in MTAP-deleted cancer models.

Mirati Therapeutics to Present New Research From its Innovative Oncology Pipeline at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer

Mirati (MRTX) reports positive data from a cohort of the phase I/IIstudy evaluating its KRAS inhibitor adagrasib in patients with KRAS G12C-mutated colorectal cancer.

Mirati (MRTX) Reports Positive Data From Colorectal Cancer Study

Amid data readouts from adagrasib, sitravatinib programs, Mirati Therapeutics Inc (NASDAQ: MRTX) has appointed David Meek as Chief Executive Officer, effective immediately.  Related:   Mirati Posts Adagrasib Data In KRAS-Mutated Lung Cancer, FDA Filing Now On The Cards.

New CEO At Mirati Therapeutics

Mirati Therapeutics Inc (NASDAQ: MRTX) has announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500 of sitravatinib combined with Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab). The trial included 68 patients with second or third-line non-squamous non-small cell lung cancer (NSCLC) who experienced clinical benefit on a prior checkpoint inhibitor (CPI) and subsequent disease progression.

Mirati Unveils Long-term Survival Data For Sitravatinib/Nivolumab Combo In Lung Cancer Patients

SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500.

Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors

SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced the appointment of David Meek as Chief Executive Officer (CEO), effective immediately.

Mirati Therapeutics Appoints David Meek as Chief Executive Officer

SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced positive topline results from the potentially registration-enabling cohort of the Phase 2 KRYSTAL-1 study, evaluating adagrasib in patients with advanced non-small cell lung cancer (NSCLC) harboring the KRAS G12C mutation following prior systemic therapy.

Mirati Therapeutics Announces Positive Phase 2 Topline Results for Investigational Adagrasib in Patients with KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

SAN DIEGO, Sept. 15, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the Company will host a virtual Investor Event on Monday, September 20, 2021 at 8:30 a.m.

Mirati Therapeutics to Host Virtual Investor Event on Monday, September 20, 2021

SAN DIEGO, Aug. 25, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced two oral presentations of clinical data will be presented at the upcoming European Society for Medical Oncology Congress (ESMO) 2021, reinforcing the clinical benefit of adagrasib, a KRASG12C inhibitor, and sitravatinib, a receptor tyrosine kinase inhibitor. The congress will take place virtually from September 16 to 21, 2021.

Mirati Therapeutics Clinical Research at ESMO Congress 2021 to Highlight Progress with Investigational Adagrasib and Sitravatinib in Patients with Lung and Colorectal Cancers

News for Mirati Therapeutics Stock (MRTX)